Atazanavir

Active ingredient description

Atazanavir is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Atazanavir
J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE08

Medicines

Atazanavir is the active ingredient of these drugs:

Drug
Countries

Ecuador

South Africa

South Africa

South Africa

Ecuador

Australia Austria Brazil Canada Cyprus

South Africa

South Africa

South Africa

Atazanavir is also found within below combination drugs:

EVOTAZ , RIATEM , RITOATAZ

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 704.856 g/mol

External identifiers

CAS Substance: 198904-31-3
DrugBank Drug: DB01072
KEGG Drug: D07471
RxNorm Ingredient: 343047
SNOMED-CT Concept: 413592000
Atazanavir (substance)
UNII Identifier: QZU4H47A3S
ATAZANAVIR